SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Denies Somaxon Pharmaceuticals, Inc. Approval for Insomnia Drug

February 27, 2009 | 
1 min read
Feb 26 (Reuters) - Somaxon Pharmaceuticals Inc said the U.S. health regulators denied approval for its experimental treatment for insomnia in the present form and raised several issues regarding the efficacy data of the drug.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Entrance to the U.S. Department of Health and Human Services in Washington, DC
Layoffs
HHS Begins Formally Laying Off Employees
July 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Policy
FDA Commissioner Marty Makary Proposes Lowering Industry User Fees
July 15, 2025
 · 
2 min read
 · 
Tristan Manalac
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
 · 
6 min read
 · 
Lori Ellis
Contemporary art collage. Giang hand kicking office worker symbolizing dismissal. Unsuccessful employee. Job reduction. Concept of business, career, failure, success, troubles
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
July 14, 2025
 · 
2 min read
 · 
Tristan Manalac